Table 3.3. Gastric Ulcer Risk-Reduction Rates in Patients Whose NSAID
was Naproxen Only or Naproxen and Aspirin Only
Table 5.1. Examples of Prices of Combination Products Compared to
the Individual Components Added Together
Table 6.1. Examples of Fixed-Dose Combination Products From Various
Therapeutic Areas
Table 6.2. Classification and Management of Blood Pressure for Adults
Table 6.4. Antiretroviral Agents Approved for the Treatment of HIV
Infection
Table 6.5. Price Comparison of Arthrotec 75 in Comparison to the
Individual Components
Table 6.6. Combination Antibiotics According to Class
Table 6.7. Ratio of Male and Female Medical, Law, Dental, and Business
Students From
1960-2000
Table 6.8. Low-Dose Oral Contraceptives Currently Available in the
United States
Table 6.9. Licensed Vaccines in Combination
Table 6.10. Drug-Eluting Coronary Stents Currently Available
Table 6.11. Drug-Eluting Coronary Stents in Clinical Trials
Table 6.12. Currently Available Helicobacter pylori Detection Tests
Table 6.13. Wound-Care Combination Products Currently Available
Table 6.14. Monoclonal Antibodies (Monotherapy) Currently Available
Table 8.1. Value Proposition and Opportunities of Different Types
of Combination Products
Figure 1.1. Patent Issues Throughout the Product Lifecycle Stages
Figure 1.2. Development Process Regarding Timelines and Regulatory
Procedures
Figure 2.1. Combinations of Previously Marketed Drugs: Recommended
General Procedure
Figure 2.2. Combinations of Previously Marketed Drugs with NMEs:
Recommended General Procedure
Figure 2.3. Combinations of NMEs with NMEs: Recommended General
Procedure
Figure 3.1. Hypothetical Factorial Study Design for Combination
Antihypertensives
Figure 3.2. Hypothetical Factorial Study Design for Combination
Cholesterol-Lowering Drugs
Figure 4.1. Comparison of Number of Submissions to FDA Versus Cost
of Pharmaceutical Research
Figure 4.2. Pfizer’s Revenue From Lipitor Sales, 1999-2005
Figure 5.1. Increased Development Efforts Required When Combining
Two Already-Released Drugs in a Fixed-Dose Combination Product
Figure 5.2. Increased Development Efforts Required When Combining
a NBE and a Released Drug in a Fixed-Dose Combination
Figure 6.1. The Stent Procedure
Figure 6.2. Principles of PDT After Application of Metvix
Figure 6.3. LidoSite Patch and Dose Controller Combining a Transdermal
Delivery System and Topical Anesthesia
Figure 7.1. CombinatoRx’s Approach to Drug Discovery in Comparison
to Traditional Methods
Figure 7.2. CombinatoRx Compounds in Clinical Trials by Phase and
Disease Area
"CHI's Insight
Pharma Reports are
a cost-effective and reliable source
of information about the markets
we serve. The cost
for us to conduct
this kind of business
research on our
own would be
prohibitive. CHI's
Insight Pharma
Reports allow us to
keep on top of
developments in
this rapidly moving
field."
--Donald N. Halbert, Ph.D., EVP of R&D, Iconix Biosciences
A division of
Cambridge
Healthtech Institute
CHI's Insight Pharma Reports, a division of Cambridge Healthtech Institute
| 250 First Avenue | Needham, MA 02494
For more information, email
Rose LaRaia at rlaraia@healthtech.com or call 781-972-5444
